Cognition Therapeutics, Inc. (CGTX) Retains Buy Rating on START Study Progress

Cognition Therapeutics, Inc. (NASDAQ:CGTX) is among the fundamentally strong penny stocks to invest in. H.C. Wainwright has maintained a $3.00 price target for Cognition Therapeutics, Inc. (NASDAQ:CGTX), with an unchanged Buy rating. This potential upside of nearly 640% represents the company’s Phase 2 START Study enrollment success that exceeded 50%.

The START Study (NCT05531656), which is examining ervimesine (CT1812) in patients living with mild Alzheimer’s disease, is being conducted in partnership with the Alzheimer’s Clinical Trials Consortium (ACTC). The expected participants, with 540 individuals across approximately 50 sites, will receive either the drug or placebo for 18 months.

With around $81 million in grant support from the National Institute of Aging (NIA), a segment of the National Institutes of Health, Cognition Therapeutics, Inc. (NASDAQ:CGTX) has the necessary support to lead the study. The firm further outlines the clinical potential of zervimesine as the company accelerates the pace for a Phase 3 program.

Cognition Therapeutics, Inc. (NASDAQ:CGTX), based in New York, is a clinical-stage biopharmaceutical company that identifies and develops small molecule therapeutics aimed at age-related degenerative diseases and disorders of the central nervous system and retina. Incorporated in 2007, the company is committed to improving the lives of many.

While we acknowledge the potential of CGTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.